Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Jun 2023

Sarfaty Michal, Golkaram Mahdi, Funt Samuel A, Al-Ahmadie Hikmat, Kaplan Shannon, Song Fan, Regazzi Ashley, Makarov Vladimir, Kuo Fengshen, Ostrovnaya Irina, Seshan Venkatraman, Zhao Chen, Greenbaum Benjamin, Liu Li, Rosenberg Jonathan E, Chan Timothy A

Abstract excerpt

PURPOSE: Immune checkpoint blockade (ICB) therapy has significantly improved clinical outcomes in bladder cancer. Identification of correlates of benefit is critical to select appropriate therapy for individual patients. METHODS: To reveal genetic variables associated with benefit from ICB, we performed whole-exome sequencing on tumor specimens from 88 patients with advanced bladder cancer treated with ICB....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Bladder and Urothelial Cancer Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Immunotherapy and Biomarkers

Share to Carcinoma, Transitional Cell

Share to Ferroptosis and cancer prognosis

Share to Immune Checkpoint Inhibitors

Share to Mutation

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 36927002
DOI: 10.1200/JCO.22.02144
PMCID: PMC10256354

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.PMID 36927002Read ↗

DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypesSemantic proximity Read ↗

Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy.Semantic proximity Read ↗

Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohortsSemantic proximity Read ↗

Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.Semantic proximity Read ↗

Identification of an immunotherapy-responsive molecular subtype of bladder cancer.Semantic proximity Read ↗

Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.Semantic proximity Read ↗

Bladder Cancer Exhibiting High Immune Infiltration Shows the Lowest Response Rate to Immune Checkpoint InhibitorsSemantic proximity Read ↗

The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival ProbabilitySemantic proximity Read ↗

Identification of Four Immune Subtypes in Bladder Cancer Based on Immune Gene SetsSemantic proximity Read ↗

Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight.Semantic proximity Read ↗

Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Semantic proximity Read ↗

Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.